Hemangioendotheliomas most frequently harbor alterations in WWTR1, CAMTA1, YAP1, TSC2, and TFE3 .
WWTR1-CAMTA1 Fusion, CAMTA1-WWTR1 Fusion, YAP1-TFE3 Fusion, YAP1 Fusion, and TFE3 Fusion are the most common alterations in hemangioendothelioma .
There are 2 clinical trials for hemangioendothelioma, of which 2 are open and 0 are completed or closed. Of the trials that contain hemangioendothelioma as an inclusion criterion, 1 is phase 1/phase 2 (1 open) and 1 is phase 4 (1 open).
Nivolumab, propranolol, and sirolimus are the most common interventions in hemangioendothelioma clinical trials.
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.